SOURCE: Kalytera Therapeutics, Inc.

Kalytera Therapeutics, Inc.

July 05, 2016 08:30 ET

Kalytera Therapeutics to Present New Data That Supports the Continued Investigation of KAL671 for the Treatment of Osteoporosis in Prader-Willi Syndrome at the IPWSO Conference

MANHATTAN BEACH, CA--(Marketwired - Jul 5, 2016) - Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, is scheduled to present at the International Prader-Willi Syndrome Organization ("IPWSO") Conference on Friday, July 22, 2016. The event is being held at the Sheraton Hotel in Toronto, Ontario, Canada.

During the presentation, Fatty Acyl Amides as Novel Therapeutics for the Treatment of Osteoporosis in PWS, Dr. Yossi Tam, D.M.D, Ph.D., a researcher at Hebrew University and a member of Kalytera's Scientific Advisory Board, will summarize recent progress in the development of KAL671. KAL671 is a unique synthetic fatty acid amide and an endocannabinoid-like molecule that may restore bone in persons suffering from osteoporosis and Prader-Willi syndrome ("PWS"). Kalytera has exclusively licensed KAL671 from Yissum Research Development Company, the technology transfer arm of Hebrew University.

Kalytera's preclinical research seeks to evaluate the use of KAL671 for treating osteoporosis in Magel2-null mice, a PWS animal model. Magel2-null mice have a low bone mass phenotype and shorter femora in comparison to their wild-type controls.

PWS is an orphan genetic disorder caused by deletions in the 15th chromosome. PWS occurs in approximately one out of every 15,000 births. At a very early age, persons with PWS develop an insatiable appetite that may lead to chronic overeating and obesity. Many patients with PWS are also diagnosed with osteoporosis; this additional symptom may occur in both children and adults with PWS.

Data from prior preclinical testing suggests that KAL671 may have potential as a new treatment for osteoporosis, as well as the symptoms of osteoporosis seen in PWS. KAL671 may offer advantages over existing osteoporosis therapies which are commonly either anti-resorptive or proformative. KAL671 is a novel treatment approach that may be both anti-resorptive and proformative, potentially representing a major advance in the treatment of osteoporosis.

Event Details

About Kalytera Therapeutics
Kalytera Therapeutics is developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines that we believe will address large unmet market needs. Kalytera seeks to commercialize its cannabinoid therapies across a range of disease states, with an initial focus on bone health.

Forward-Looking Statement Disclosure
This press release contains certain "forward-looking statements", including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information

  • Company Contact
    Robert Farrell
    President and CFO
    Phone: (888) 861-2008
    Email: info@kalytera.co